Fig. 2

Cost-effectiveness plots from a reduced third payer perspective. a Beta-lactam/macrolide strategy vs. beta-lactam strategy-90-day time horizon. b Beta-lactam/macrolide strategy vs. beta-lactam strategy-30-day time horizon. c Fluoroquinolone monotherapy strategy vs. beta-lactam strategy-90-day time horizon. d Fluoroquinolone monotherapy strategy vs. beta-lactam strategy-30-day time horizon. Legend: Grey points represent incremental costs and incremental effects of 2,000 bootstrapping samples for the beta-lactam/macrolide combination strategy compared to the beta-lactam monotherapy strategy within 90 (a) and 30 (b) days of admission, and for the fluoroquinolone monotherapy strategy compared to the beta-lactam monotherapy strategy within 90 (c) and 30 (d) days of admission. The black points and curves represent the point estimates and the 95% confidence ellipses. Proportions in each quadrant indicate the proportion of bootstrap samples in that quadrant. Point estimates in the north-west quadrant are in favour of the beta-lactam monotherapy strategy; point estimates in the south-east quadrant are in favour of the other strategy. Exact point estimates and 95% confidence intervals for incremental costs and incremental effects are given in Additional file 1: Table S3